Phreesia, Inc. (NYSE: PHR) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 82.19 | EPS (ttm) | 0.15 | Insider Own | 20.78% | Shs Outstand | 61.81M | Perf Week | 16.59% |
| Market Cap | 773.27M | Forward P/E | 18.70 | EPS next Y | 0.67 | Insider Trans | 21.96% | Shs Float | 49.35M | Perf Month | 15.62% |
| Enterprise Value | 791.12M | PEG | - | EPS next Q | 0.11 | Inst Own | - | Short Float | 7.13% | Perf Quarter | 27.26% |
| Income | 9.28M | P/S | 1.56 | EPS this Y | 166.56% | Inst Trans | - | Short Ratio | 2.56 | Perf Half Y | -0.64% |
| Sales | 495.59M | P/B | 2.12 | EPS next Y | 67.35% | ROA | 1.38% | Short Interest | 3.52M | Perf YTD | -26.06% |
| Book/sh | - | P/C | 8.68 | EPS next 5Y | 25.44% | ROE | 2.79% | 52W High | 32.46 -61.81% | Perf Year | -53.85% |
| Cash/sh | - | P/FCF | 10.63 | EPS past 3/5Y | - | ROIC | -6.19% | 52W Low | 7.70 61.00% | Perf 3Y | -57.65% |
| Dividend Est. | - | EV/EBITDA | 18.65 | Sales past 3/5Y | 19.62% 26.41% | Gross Margin | 65.81% | Volatility | 3.68% 3.99% | Perf 5Y | -81.70% |
| Dividend TTM | - | EV/Sales | 1.60 | EPS Y/Y TTM | 114.71% | Oper. Margin | 0.73% | ATR (14) | 0.56 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.76 | Sales Y/Y TTM | 17.86% | Profit Margin | 1.85% | RSI (14) | 71.33 | Recom | 2.28 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.76 | EPS Q/Q | 145.45% | SMA20 | 15.00% | Beta | 0.85 | Target Price | 12.17 |
| Payout | 0.00% | Debt/Eq | 0.26 | Sales Q/Q | 12.93% | SMA50 | 21.85% | Rel Volume | 0.93 | Prev Close | 12.51 |
| Employees | 1,789 | LT Debt/Eq | 0.28 | Earnings | Sep 03 | SMA200 | -6.49% | Avg Volume | 1.22M | Price | 12.39 |
| IPO Date | Jul 18, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 337.06% 0.66% | Net Debt/EBITDA | 0.42 | Volume | 1,126,137 | Change | -0.92% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-28-26 | Reiterated | Piper Sandler | Overweight | $30 → $12 |
| May-28-26 | Reiterated | DA Davidson | Buy | $30 → $14 |
| May-28-26 | Reiterated | Canaccord Genuity | Buy | $33 → $16 |
| May-20-26 | Downgrade | Wells Fargo | Overweight → Equal Weight | $30 → $9.00 |
| May-15-26 | Downgrade | Barclays | Overweight → Equal Weight | $10 |
| Apr-01-26 | Downgrade | Citizens | Market Outperform → Market Perform | |
| Mar-31-26 | Downgrade | Citigroup | Buy → Neutral | |
| Mar-31-26 | Downgrade | Truist Securities | Buy → Hold | |
| Mar-31-26 | Downgrade | JP Morgan | Overweight → Neutral | |
| Mar-31-26 | Downgrade | Baird | Outperform → Neutral |
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2026 1/31/2026 | FY 2025 1/31/2025 | FY 2024 1/31/2024 | FY 2023 1/31/2023 | FY 2022 1/31/2022 | FY 2021 1/31/2021 | FY 2020 1/31/2020 | FY 2019 1/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 495 | 481 | 420 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 169 | 154 | 135 | — | — | — | — | — | — | |
| Gross Profit | 327 | 326 | 285 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 181 | 180 | 198 | — | — | — | — | — | — | |
| Research and Development | 117 | 121 | 117 | — | — | — | — | — | — | |
| Other Operating Expense | 25 | 32 | 28 | — | — | — | — | — | — | |
| Operating Income | 3 | -7 | -58 | — | — | — | — | — | — | |
| Interest Expense | 9 | 7 | 2 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 4 | 5 | 5 | — | — | — | — | — | — | |
| Net Income Before Taxes | -1 | -9 | -56 | — | — | — | — | — | — | |
| Income Taxes | -10 | -11 | 3 | — | — | — | — | — | — | |
| Consolidated Net Income | 9 | 2 | -59 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 9 | 2 | -59 | — | — | — | — | — | — | |
| Net Income | 9 | 2 | -59 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.15 | 0.04 | -1.02 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.15 | 0.04 | -1.02 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.15 | 0.04 | -1.02 | — | — | — | — | — | — | |
| EBITDA | 42 | 29 | -26 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 82.63 | 358.13 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.53 | 1.68 | 3.93 | — | — | — | — | — | — | |
| Gross Margin | 66.06 | 67.78 | 67.86 | — | — | — | — | — | — | |
| Operating Margin | 0.61 | -1.46 | -13.81 | — | — | — | — | — | — | |
| Net Margin | 1.82 | 0.42 | -14.05 | — | — | — | — | — | — | |
| Shares Outstanding | 61 | 60 | 58 | — | — | — | — | — | — | |
| Market Capitalization | 756 | 806 | 1,651 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hui Yvonne | Principal Accounting Officer | Jul 16 '26 | Sale | 10.92 | 1,247 | 13,617 | 21,724 | Jul 17 |
| Egbuonu-Davis Lisa | Director | Jul 14 '26 | Sale | 10.70 | 536 | 5,735 | 37,780 | Jul 16 |
| Hui Yvonne | Principal Accounting Officer | Jul 06 '26 | Sale | 10.84 | 1,371 | 14,862 | 23,908 | Jul 07 |
| Egbuonu-Davis Lisa | Director | Jun 25 '26 | Sale | 9.53 | 2,546 | 24,263 | 38,316 | Jun 26 |
| Hui Yvonne | Principal Accounting Officer | May 18 '26 | Sale | 8.85 | 431 | 3,814 | 24,233 | May 20 |
| Hoffman Allison C | General Counsel & Secretary | Apr 20 '26 | Sale | 9.06 | 6,176 | 55,955 | 157,309 | Apr 21 |
| Hui Yvonne | Principal Accounting Officer | Apr 17 '26 | Sale | 9.28 | 1,327 | 12,315 | 24,664 | Apr 21 |
| Hui Yvonne | Principal Accounting Officer | Apr 16 '26 | Sale | 9.08 | 10,063 | 91,372 | 25,991 | Apr 17 |
| Linetsky David | President, Network Solutions | Apr 10 '26 | Sale | 8.07 | 8,332 | 67,239 | 224,056 | Apr 13 |
| Hoffman Allison C | General Counsel & Secretary | Apr 10 '26 | Sale | 8.07 | 14,483 | 116,878 | 163,485 | Apr 13 |
| Pale Fire Capital SE | 10% Owner | Apr 02 '26 | Buy | 8.31 | 106,236 | 882,407 | 8,924,329 | Apr 02 |
| Pale Fire Capital SE | 10% Owner | Apr 01 '26 | Buy | 8.43 | 168,764 | 1,421,938 | 8,818,093 | Apr 02 |
| Pale Fire Capital SE | 10% Owner | Mar 31 '26 | Buy | 8.16 | 1,000,500 | 8,160,478 | 8,649,329 | Apr 02 |
| Gandhi Balaji | Chief Financial Officer | Mar 25 '26 | Sale | 11.26 | 3,829 | 43,128 | 146,740 | Mar 27 |
| Hoffman Allison C | General Counsel & Secretary | Mar 23 '26 | Sale | 11.97 | 6,176 | 73,927 | 163,485 | Mar 25 |